DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Income from Continuing Operations came in at 10042000.0 in Q1 2026, down 30.3% year-on-year from 14406867.83 in Q1 2025, and down 164.19% quarter-over-quarter from 3801000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 10042000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 30.3% year-over-year to 10042000.0 in Q1 2026; TTM through Mar 2026 was 30162000.0, a 11.71% decrease from a year earlier, with the FY2025 full-year figure at 27827000.0, down 13.84% from the prior year.
- Income from Continuing Operations eased to 10042000.0 in Q1 2026 per DMAC's latest filing, from 3801000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 3059000.0 in Q3 2022 and bottomed at 10042000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 5151000.0 (2024), against an average of 5610000.0.
- Across the five-year window, Income from Continuing Operations plunged 53.07% in 2024 and surged 51.89% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 3751000.0 in 2022, then slumped by 37.59% to 5161000.0 in 2023, then tumbled by 53.07% to 7900000.0 in 2024, then surged by 51.89% to 3801000.0 in 2025, then tumbled by 164.19% to 10042000.0 in 2026.
- Per Business Quant, the three latest DMAC Income from Continuing Operations figures stand at 10042000.0 (Q1 2026), 3801000.0 (Q4 2025), and 8620000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | DiaMedica Therapeutics | 364.72 Mn | 364.72 Mn | - | -10.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.04 Mn |
| Dec 31, 2025 | -3.80 Mn |
| Sep 30, 2025 | -8.62 Mn |
| Jun 30, 2025 | -7.70 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -7.90 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Jun 30, 2024 | -5.12 Mn |
| Mar 31, 2024 | -5.15 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | -4.47 Mn |
| Jun 30, 2023 | -4.48 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -3.36 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.45 Mn |
| Jun 30, 2021 | -3.27 Mn |